1. Delamanid-containing regimens and multidrug-resistant tuberculosis
- Author
-
Mohammad Javad Nasiri, Moein Zangiabadian, Erfan Arabpour, Sirus Amini, Farima Khalili, Rosella Centis, Lia D'Ambrosio, Justin T. Denholm, H. Simon Schaaf, Martin van den Boom, Xhevat Kurhasani, Margareth Pretti Dalcolmo, Seif Al-Abri, Jeremiah Chakaya, Jan-Willem Alffenaar, Onno Akkerman, Denise Rossato Silva, Marcela Muňoz-Torrico, Barbara Seaworth, Emanuele Pontali, Laura Saderi, Simon Tiberi, Alimuddin Zumla, Giovanni Battista Migliori, Giovanni Sotgiu, and Microbes in Health and Disease (MHD)
- Subjects
Microbiology (medical) ,Treatment Outcome ,Infectious Diseases ,Nitroimidazoles ,Tuberculosis, Multidrug-Resistant ,Antitubercular Agents ,wf_360 ,Humans ,General Medicine ,wf_200 ,Diarylquinolines ,Oxazoles ,qw_45 - Abstract
Introduction\ud \ud Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety.\ud \ud Methods\ud \ud We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P 0.05).\ud \ud Conclusions\ud \ud In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.
- Published
- 2022